UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 160

Sortiert nach

Infancia mapuche encerrada: internados de las escuelas-misiones en la Araucanía, Chile (1900-1935)

Revista Brasileira de Educação, 2018, Vol.23

2018

Link zum Volltext

Verfügbarkeit prüfen

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Cell reports (Cambridge), 2018-03, Vol.22 (11), p.2978-2994

2018

Link zum Volltext

Verfügbarkeit prüfen

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Oncotarget, 2017-09, Vol.8 (41), p.69493-69507

2017

Link zum Volltext

Verfügbarkeit prüfen

p38 mitogen‐activated protein kinase inhibitor LY2228820 enhances bortezomib‐induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications

British journal of haematology, 2008-06, Vol.141 (5), p.598-606

2008

Link zum Volltext

Verfügbarkeit prüfen

Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts

Clinical cancer research, 2014-07, Vol.20 (14), p.3763-3774

2014

Link zum Volltext

Verfügbarkeit prüfen

A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models

Molecular cancer therapeutics, 2014-06, Vol.13 (6), p.1442-1456

2014

Link zum Volltext

Verfügbarkeit prüfen

Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy

NPJ breast cancer, 2022-11, Vol.8 (1), p.126-126, Article 126

2022

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy

NPJ breast cancer, 2022-12, Vol.8 (1), p.133-133, Article 133

2022

Link zum Volltext

Verfügbarkeit prüfen

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)

Bioorganic & medicinal chemistry letters, 2019-10, Vol.29 (20), p.126637-126637, Article 126637

2019

Link zum Volltext

Verfügbarkeit prüfen

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs

Bioorganic & medicinal chemistry letters, 2015-09, Vol.25 (17), p.3420-3435

2015

Link zum Volltext

Verfügbarkeit prüfen

Total Synthesis of (+)-Aspidospermidine: A New Strategy for the Enantiospecific Synthesis of Aspidosperma Alkaloids

Journal of the American Chemical Society, 2002-11, Vol.124 (45), p.13398-13399

2002

Link zum Volltext

Verfügbarkeit prüfen

Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

Drug metabolism and disposition, 2015-09, Vol.43 (9), p.1360-1371

2015

Link zum Volltext

Verfügbarkeit prüfen

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Investigational new drugs, 2014-10, Vol.32 (5), p.825-837

2014

Link zum Volltext

Verfügbarkeit prüfen

Acyl sulfonamide anti-proliferatives. Part 2: Activity of heterocyclic sulfonamide derivatives

Bioorganic & medicinal chemistry letters, 2005-02, Vol.15 (3), p.617-620

2005

Link zum Volltext

Verfügbarkeit prüfen

Abemaciclib, a CDK4 and 6 inhibitor with unique pharmacological properties for breast cancer therapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e12506-e12506

2021

Link zum Volltext

Verfügbarkeit prüfen

Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation

Oncotarget, 2022-07, Vol.13 (1), p.864-875

2022

Link zum Volltext

Verfügbarkeit prüfen

Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity

Molecular cancer therapeutics, 2014-02, Vol.13 (2), p.364-374

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1236-1236

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2836: Characterization of the mechanism of action for abemaciclib with antiestrogen combined therapy in human breast cancer cell lines

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2836-2836

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.583-583

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4569: The CDK4/6 inhibitor abemaciclib synergizes with PD-L1 blockade to induce an immune inflamed tumor microenvironment through T cell and tumor cell intrinsic effects

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4569-4569

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3104: Molecular features that determine the sensitivity of cancer cells to abemaciclib, an inhibitor of CDK4 and CDK6

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3104-3104

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3101: In-vitro characterization of Abemaciclib pharmacology in ER+ breast cancer cell lines

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3101-3101

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2829: Preclinical analysis and characterization of abemaciclib using three-dimensional patient-derived colorectal cancer organoid cultures

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2829-2829

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 160

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(143)
Mit Volltextzugriff
(153)

Publikationsform

Artikel
(158)
Buchkapitel
(1)
Texte
(1)

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Infancia mapuche encerrada: internados de las escuelas-misiones en la Araucanía, Chile (1900-1935)

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

p38 mitogen‐activated protein kinase inhibitor LY2228820 enhances bortezomib‐induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications

Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts

A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models

Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy

Author Correction: Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs

Total Synthesis of (+)-Aspidospermidine: A New Strategy for the Enantiospecific Synthesis of Aspidosperma Alkaloids

Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Acyl sulfonamide anti-proliferatives. Part 2: Activity of heterocyclic sulfonamide derivatives

Abemaciclib, a CDK4 and 6 inhibitor with unique pharmacological properties for breast cancer therapy

Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation

Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity

Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)

Abstract 2836: Characterization of the mechanism of action for abemaciclib with antiestrogen combined therapy in human breast cancer cell lines

Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade

Abstract 4569: The CDK4/6 inhibitor abemaciclib synergizes with PD-L1 blockade to induce an immune inflamed tumor microenvironment through T cell and tumor cell intrinsic effects

Abstract 3104: Molecular features that determine the sensitivity of cancer cells to abemaciclib, an inhibitor of CDK4 and CDK6

Abstract 3101: In-vitro characterization of Abemaciclib pharmacology in ER+ breast cancer cell lines

Abstract 2829: Preclinical analysis and characterization of abemaciclib using three-dimensional patient-derived colorectal cancer organoid cultures

Suchergebnisse filtern